{"id":"asp1517","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2338329","moleculeType":"Small molecule","molecularWeight":"352.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NLRP3 inflammasome inhibition is a novel therapeutic strategy for treating inflammatory diseases. By blocking the NLRP3 inflammasome, ASP1517 aims to reduce the production of pro-inflammatory cytokines, such as IL-1β and IL-18, which are involved in the pathogenesis of various inflammatory conditions.","oneSentence":"ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:28.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of gout"}]},"trialDetails":[{"nctId":"NCT05970172","phase":"PHASE3","title":"A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-01-16","conditions":"Chronic Kidney Disease, Renal Anemia","enrollment":100},{"nctId":"NCT04408820","phase":"","title":"Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2020-06-01","conditions":"Renal Anemia","enrollment":2104},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT01887600","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-03","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":594},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT02779764","phase":"PHASE3","title":"A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-05-16","conditions":"Hemodialysis Patients With Renal Anemia","enrollment":164},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT02964936","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-11","conditions":"Chronic Kidney Disease","enrollment":100},{"nctId":"NCT03643601","phase":"","title":"A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Astellas Pharma a/s","startDate":"2018-09-24","conditions":"Chronic Kidney Disease Associated Anemia","enrollment":14415},{"nctId":"NCT03960489","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-07-31","conditions":"Healthy Adult Subjects","enrollment":24},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":"Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":303},{"nctId":"NCT02780141","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-02","conditions":"ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":75},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT02780726","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-22","conditions":"Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia","enrollment":56},{"nctId":"NCT01964196","phase":"PHASE2","title":"ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-09-17","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":107},{"nctId":"NCT01083888","phase":"PHASE1","title":"ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02-15","conditions":"Anemia, Hemodialysis, Renal Impairment","enrollment":12},{"nctId":"NCT03263091","phase":"PHASE3","title":"Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2018-01-29","conditions":"Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia","enrollment":184},{"nctId":"NCT01750190","phase":"PHASE3","title":"A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2012-11-05","conditions":"CKD Anemia","enrollment":922},{"nctId":"NCT02052310","phase":"PHASE3","title":"Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2014-02-11","conditions":"Anemia in Incident Dialysis Patients","enrollment":1043},{"nctId":"NCT02965040","phase":"PHASE1","title":"A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-12-12","conditions":"Normal Renal Function, Impaired Renal Function","enrollment":34},{"nctId":"NCT02952040","phase":"PHASE1","title":"A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT02805374","phase":"PHASE1","title":"A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-07","conditions":"Healthy Subjects","enrollment":16},{"nctId":"NCT02693613","phase":"PHASE1","title":"Pharmacokinetic Study of ASP1517 With Kremezin®","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-02","conditions":"Healthy Volunteers","enrollment":34},{"nctId":"NCT02252731","phase":"PHASE1","title":"A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":"Pharmacokinetics of FG-4592, Healthy Subjects","enrollment":22},{"nctId":"NCT02161796","phase":"PHASE1","title":"A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":"PK for FG-4592, Healthy Subjects","enrollment":48},{"nctId":"NCT02161224","phase":"PHASE1","title":"A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":"PK of FG-4592, Hepatic Insufficiency, Healthy Subjects","enrollment":16},{"nctId":"NCT00978198","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FG-4592"],"phase":"phase_2","status":"active","brandName":"ASP1517","genericName":"ASP1517","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome. Used for Treatment of gout.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}